Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, ...
A study published in JAMA Ophthalmology 1 reported that spectacle lenses with highly aspherical lenslets (HAL) are safe and ...
How should clinicians recognize Demodex blepharitis, and which specialists should be looking for it? These questions framed a recent Ophthalmology Times Clinical Forum in New Orleans, Louisiana: “ ...
The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...
LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
Carey said the take-home message is “if you have a patient who’s had MS and optic neuritis, and they call your office saying, ...
Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...
CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision. Fovlussea enters a European market where ranibizumab biosimilars have been commercially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results